| Commodity | Reporter | Partner | Trade flow | Indicator | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| 3002. Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc | China | World | Exports | Value (US$) | 220,992,295.00 | 304,556,673.00 | 392,779,843.00 | 393,526,748.00 | 632,703,973.00 | 574,356,200.00 | 684,085,261.00 | 727,806,448.00 | 3,681,499,312.00 | 27,170,941,064.00 | 2,023,713,746.00 | 797,821,012.00 |
| Value Growth, YoY (%) | 23.22 | 37.81 | 28.96 | 0.19 | 60.77 | -9.22 | 19.10 | 6.39 | 405.83 | 638.04 | -92.55 | -60.57 | ||||
| Imports | Value (US$) | 2,358,427,764.00 | 3,396,874,069.00 | 4,029,042,375.00 | 5,152,312,207.00 | 5,655,860,860.00 | 7,023,230,263.00 | 8,384,141,533.00 | 10,803,457,774.00 | 12,233,200,131.00 | 16,218,191,314.00 | 15,172,816,151.00 | 16,873,947,022.00 | |||
| Value Growth, YoY (%) | 37.67 | 44.03 | 18.61 | 27.87 | 9.77 | 24.17 | 19.37 | 28.85 | 13.23 | 32.57 | -6.44 | 11.21 |
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from China totalled $ 797 million in 2023. Sales of commodity group 3002 from China decreased by 60% in value terms compared to 2022. exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 1.22 billion (cumulative exports of commodity group 3002 from China amounted $2.02 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 0.023% of total exports from China (cumulative merchandise exports from China totalled $ 3.37 trillion in 2023). The share of commodity group 3002 in total exports from China decreased by 0.032 p.p. compared to 2022 (it was 0.056% in 2022 and cumulative exports from China were equal to $ 3.59 trillion).
Exports of commodity group 3002 amounted to 7.07% of total sales of group "" from China in 2023 (the value of exports of commodity group from China amounted to $11.2 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from China lowered by 7.37 p.p. compared to 2022 (it was 14.4% in 2022, and exports of commodity group from China were $14 billion).
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from China in 2023:
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to China totalled $ 16.8 billion in 2023. Sales of commodity group 3002 to China went up by 11.2% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.7 billion (the value of imports of commodity group 3002 to China was equal to $15.1 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 0.659% of total import flow to China (in 2023, total imports to China amounted to $ 2.55 trillion). The share of commodity group 3002 in total imports to China increased by 0.101 p.p. compared to 2022 (it was 0.558% in 2022 and cumulative imports to China were equal to $ 2.71 trillion).
Imports of commodity group 3002 reached 39% of total imports of group "" to China in 2023 (imports of commodity group to China totalled $43 billion in 2023). The share of purchases of commodity group 3002 in total imports of commodity group to China increased by 1.15 p.p. compared to 2022 (it was 38% in 2022, and imports of commodity group to China accounted for $39 billion).
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of China in 2023: